KR20180030630A - 아필리모드를 이용한 암 치료 방법 - Google Patents

아필리모드를 이용한 암 치료 방법 Download PDF

Info

Publication number
KR20180030630A
KR20180030630A KR1020187004110A KR20187004110A KR20180030630A KR 20180030630 A KR20180030630 A KR 20180030630A KR 1020187004110 A KR1020187004110 A KR 1020187004110A KR 20187004110 A KR20187004110 A KR 20187004110A KR 20180030630 A KR20180030630 A KR 20180030630A
Authority
KR
South Korea
Prior art keywords
composition
cancer
mode
lymphoma
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187004110A
Other languages
English (en)
Korean (ko)
Inventor
헨리 리히텐슈타인
조나단 엠. 로스버그
소피아 게일
닐 비해리
폴 베케트
션 란드레테
크리스 콘래드
티안 수
Original Assignee
램 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 램 테라퓨틱스, 인코포레이티드 filed Critical 램 테라퓨틱스, 인코포레이티드
Publication of KR20180030630A publication Critical patent/KR20180030630A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020187004110A 2015-07-20 2016-07-19 아필리모드를 이용한 암 치료 방법 Ceased KR20180030630A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562194367P 2015-07-20 2015-07-20
US62/194,367 2015-07-20
PCT/US2016/042905 WO2017015262A1 (en) 2015-07-20 2016-07-19 Methods for treating cancer using apilimod

Publications (1)

Publication Number Publication Date
KR20180030630A true KR20180030630A (ko) 2018-03-23

Family

ID=56551023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187004110A Ceased KR20180030630A (ko) 2015-07-20 2016-07-19 아필리모드를 이용한 암 치료 방법

Country Status (13)

Country Link
US (1) US10350213B2 (https=)
EP (1) EP3325014B1 (https=)
JP (2) JP2018525358A (https=)
KR (1) KR20180030630A (https=)
CN (1) CN108025076A (https=)
AU (1) AU2016297555B2 (https=)
BR (1) BR112018000776A2 (https=)
CA (1) CA2991779A1 (https=)
IL (1) IL256836B (https=)
MX (1) MX2018000715A (https=)
RU (1) RU2738934C2 (https=)
TW (1) TWI746449B (https=)
WO (1) WO2017015262A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102320190B1 (ko) 2014-01-24 2021-11-03 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 조성물 및 이를 사용하기 위한 방법
RU2739992C2 (ru) * 2014-11-07 2020-12-30 ЭйАй ТЕРАПЬЮТИКС, ИНК. Композиции апилимода и способы их применения в лечении колоректального рака
CA2966359A1 (en) 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
WO2017127661A1 (en) * 2016-01-21 2017-07-27 Lam Therapeutics, Inc. Biomarkers for treating cancer with apilimod
EP3678648B1 (en) 2017-09-08 2023-07-26 Insignis Therapeutics, Inc. Methods of using dipivefrin
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
TW202000205A (zh) 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
US20230364084A1 (en) * 2020-10-28 2023-11-16 The Regents Of The University Of Michigan Methods for preventing or treating conditions related to pikfyve activity
IL309143A (en) * 2021-06-11 2024-02-01 Orphai Therapeutics Inc Stabilized apilimod compositions and uses thereof
WO2023108110A2 (en) * 2021-12-10 2023-06-15 Verastem, Inc. Combination therapy for treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2025175564A1 (en) * 2024-02-23 2025-08-28 The Regents Of The University Of Michigan Method for treating autophagy dependent cancer with a pikfyve degrader

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
CU23475A1 (es) * 2004-07-08 2009-12-17 Ct Ingenieria Genetica Biotech Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
RU2350338C2 (ru) * 2007-05-14 2009-03-27 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения поверхностного рака мочевого пузыря
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
EP2760874A4 (en) * 2011-09-26 2015-04-08 Galera Therapeutics Llc METHOD FOR THE TREATMENT OF ILLNESSES
AU2013337717B2 (en) * 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
HK1224173A1 (zh) * 2013-03-14 2017-08-18 Pharmacyclics Llc 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2014364593A1 (en) * 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
KR102320190B1 (ko) * 2014-01-24 2021-11-03 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 조성물 및 이를 사용하기 위한 방법
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Also Published As

Publication number Publication date
TWI746449B (zh) 2021-11-21
JP2021121611A (ja) 2021-08-26
AU2016297555B2 (en) 2021-08-19
RU2018105923A (ru) 2019-08-20
RU2018105923A3 (https=) 2019-12-20
IL256836B (en) 2021-04-29
US20170020884A1 (en) 2017-01-26
RU2738934C2 (ru) 2020-12-18
BR112018000776A2 (pt) 2018-09-04
AU2016297555A1 (en) 2018-03-01
CA2991779A1 (en) 2017-01-26
HK1254258A1 (zh) 2019-07-12
EP3325014A1 (en) 2018-05-30
EP3325014B1 (en) 2021-05-19
IL256836A (en) 2018-03-29
TW201717957A (zh) 2017-06-01
WO2017015262A1 (en) 2017-01-26
MX2018000715A (es) 2018-06-06
JP2018525358A (ja) 2018-09-06
US10350213B2 (en) 2019-07-16
CN108025076A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
US11266654B2 (en) Apilimod compositions and methods for using same
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
AU2015342876B2 (en) Apilimod for use in the treatment of colorectal cancer
US20180078561A1 (en) Active metabolites of apilimod and uses thereof
HK1254258B (en) Methods for treating cancer using apilimod
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma
NZ722491B2 (en) Apilimod compositions and methods for using same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000